Dr. Lauren Kim speaks with Adarsh Mallepady and Dr. Cory Trankle about their large-scale retrospective study of nearly 4 million patients examining the risk of nephrogenic systemic fibrosis after gadolinium-based contrast administration in those with advanced renal dysfunction. They discuss how modern group 2 and macrocyclic agents were associated with an exceedingly low incidence of NSF, offering important reassurance for evidence-based contrast use and evolving clinical practice.

Nephrogenic Systemic Fibrosis in Patients with Advanced RenalDysfunction Following Gadolinium-based Contrast Agents. Mallepally et al. Radiology 2025; 317(3):e251794.

Dr. Linda Chu speaks with Dr. Kavitha Chinnaiyan and Dr. Jonathon Leipsic about why 2026 marks an inflection point for coronary CT, from AI-enabled plaque quantification to FFR-CT and evolving guideline support for CT-first evaluation of suspected coronary artery disease. They explore how advanced imaging tools are reshaping risk assessment, personalizing prevention and revascularization decisions, and strengthening collaboration between radiology and cardiology while highlighting the need for validation, standardization, and equitable access.

Dr. Reni Butler speaks with Dr. Anne Marie McCarthy and Dr. Christine Edmonds about their study examining Black–White racial differences in background parenchymal enhancement (BPE) on contrast-enhanced breast MRI. They discuss the finding that black women had higher odds of high BPE independent of breast density, explore potential biologic and environmental drivers, and consider how quantitative BPE assessment could improve breast cancer risk stratification and screening equity.

Black-White Racial Differences in Background Parenchymal Enhancement at Breast MRI. Mahmoud et al. Radiology 2026; 318(1):e251041.